HEXIM1 and neoplasm: In addition, CCR2 transcriptional suppression and HEXIM1 transcriptional activation were observed after BMS-986158 dosing, showing an on-target pharmacodynamic response and inhibition of the BET pathway, since HEXIM1 [26,27] and CCR2 mRNA [28] have been shown to be upregulated and downregulated, respectively, in tumor cell lines treated with BET inhibitors.